Hsbc Holdings PLC Buys 12,280 Shares of Allogene Therapeutics, Inc. $ALLO

Hsbc Holdings PLC boosted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 17.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,435 shares of the company’s stock after purchasing an additional 12,280 shares during the period. Hsbc Holdings PLC’s holdings in Allogene Therapeutics were worth $115,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ALLO. Dimensional Fund Advisors LP lifted its stake in Allogene Therapeutics by 30.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock valued at $7,586,000 after purchasing an additional 831,146 shares during the last quarter. Northern Trust Corp lifted its stake in Allogene Therapeutics by 4.5% in the 4th quarter. Northern Trust Corp now owns 1,305,232 shares of the company’s stock valued at $2,780,000 after purchasing an additional 56,693 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Allogene Therapeutics by 14.0% in the 4th quarter. Ameriprise Financial Inc. now owns 201,943 shares of the company’s stock valued at $430,000 after purchasing an additional 24,830 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Allogene Therapeutics by 1,732.2% during the fourth quarter. BNP Paribas Financial Markets now owns 849,658 shares of the company’s stock valued at $1,810,000 after acquiring an additional 803,284 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Allogene Therapeutics by 99.3% during the fourth quarter. Bank of America Corp DE now owns 1,163,743 shares of the company’s stock valued at $2,479,000 after acquiring an additional 579,818 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Up 3.6%

ALLO stock opened at $1.15 on Friday. The firm has a market cap of $255.16 million, a price-to-earnings ratio of -1.04 and a beta of 0.36. Allogene Therapeutics, Inc. has a 12-month low of $0.86 and a 12-month high of $3.78. The company’s fifty day simple moving average is $1.19 and its 200 day simple moving average is $1.39.

Allogene Therapeutics (NASDAQ:ALLO) last released its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. Research analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ALLO. Piper Sandler dropped their price target on shares of Allogene Therapeutics from $9.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Allogene Therapeutics in a research note on Monday, August 4th. Wall Street Zen raised shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 30th. Citizens Jmp downgraded shares of Allogene Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, May 14th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research note on Wednesday, May 14th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.44.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).